Search Within

Saad Zafar Usmani

  1. "2024"
Formats
  1. Meeting Abstract (44)
  2. Journal Article (24)
  3. Research Letter (3)
  4. Review (2)
  5. Editorial (1)
  6. Guidelines (1)
Groups
  1. Graduate Medical Education (45)
  2. Hematologic Malignancies, Division of (45)
  3. Department of Medicine (44)
  4. Center for Hematologic Malignancies (41)
  5. GME, Medicine (40)
  6. Myeloma (39)

More Groups

People
  1. Kylee Maclachlan (38)
  2. Alexander Lesokhin (33)
  3. Sham Mailankody (33)
  4. Urvi Shah (33)
  5. Carlyn Rose Tan (31)
  6. Malin Hultcrantz (30)

More People

Years
  1. 2024 (75)
Publications
  1. Clinical Lymphoma, Myeloma and Leukemia (23)
  2. Blood (18)
  3. Blood Advances (8)
  4. Blood Cancer Journal (6)
  5. Journal of Clinical Oncology (6)
  6. International Journal of Radiation Oncology, Biology, Physics (4)

More Publications

Publishers
  1. Elsevier Inc. (27)
  2. American Society of Hematology (26)
  3. Nature Publishing Group (7)
  4. American Society of Clinical Oncology (6)
  5. American Association for Cancer Research (2)
  6. Elsevier Science, Inc. (2)

More Publishers

Results (75)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Genomic determinants of resistance to anti-BCMA chimeric antigen receptor T-cell (CART) therapies in patients with relapsed/refractory multiple myeloma
    Meeting Abstract

    Maura, F.; Freeman, C. L.; Lee, H.; Maclachlan, K. H.; Durante, M.; Ziccheddu, B.; Menges, M.; Diamond, B.; Papadimitriou, M.; Silva, A. S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Genomic complexity correlates with the degree of marrow independence of malignant plasma cells in the context of extramedullary disease
    Meeting Abstract

    Maclachlan, K. H.; Garces, J. J.; Shekarkhand, T.; Rajeeve, S.; Hashmi, H.; Hassoun, H.; Hultcrantz, M.; Korde, N.; Tan, C. R.; Mailankody, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Real-world safety and early efficacy of talquetamab in patients with heavily-pretreated relapsed/refractory multiple myeloma
    Meeting Abstract

    Costa, B. A.; Tan, C. R.; Shekarkhand, T.; Firestone, R. S.; Jurgens, E. M.; Miller, K.; Lesokhin, A. M.; Shah, G. L.; Korde, N.; Rajeeve, S.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Defining the rates of cytokine release syndrome associated with talquetamab step-up doses
    Meeting Abstract

    Hamadeh, I. S.; Shekarkhand, T.; Rueda, C.; Firestone, R. S.; Wang, A. X.; Korde, N.; Hultcrantz, M.; Lesokhin, A. M.; Mailankody, S.; Hassoun, H.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Comparison of acute kidney injury in patients with relapsed or refractory multiple myeloma following CAR T-cell and bispecific antibody therapies
    Meeting Abstract

    Nishimura, N.; Mailankody, S.; Nemirovsky, D.; Derkach, A.; Costa, B. A.; Farzana, T.; Shaikh, A.; Latcha, S.; Gutgarts, V.; Jurgens, E. M.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Body mass index trajectory during triplet induction therapy: Clinical implications in newly diagnosed multiple myeloma
    Meeting Abstract

    Thirugnanasambandam, R. P.; Firestone, R. S.; Derkach, A.; Furberg, H.; Shekarkhand, T.; Rueda, C.; Maclachlan, K. H.; Hultcrantz, M.; Mailankody, S.; Patel, D.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Infectious complications during treatment with commercial CAR T-cell therapy and bispecific antibodies for relapsed/refractory multiple myeloma
    Meeting Abstract

    Jurgens, E. M.; Shekarkhand, T.; Farzana, T.; Rueda, C.; Nemirovsky, D.; Derkach, A.; Firestone, R. S.; Nishimura, N.; Miller, K.; Costa, B. A.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • High WEE1 expression correlates with poor survival in multiple myeloma, independent of standard prognostic factors
    Meeting Abstract

    Simhal, A. K.; Firestone, R. S.; Oh, J. H.; Norton, L.; Hultcrantz, M.; Usmani, S. Z.; Maclachlan, K. H.; Deasy, J. O.
    Blood (2024)

    Fulltext@MSK | Save
  • Manufacture of anti-BCMA CAR T cell is feasible after salvage autologous or allogeneic hematopoietic stem cell transplantation
    Meeting Abstract

    Shah, G. L.; Perica, K.; Nagel, K.; Payson, E.; Hosszu, K. K.; Chung, D. J.; Landau, H. J.; Scordo, M.; Hultcrantz, M.; Korde, N.; more...
    Blood (2024)

    Fulltext@MSK | Save
  • Radiation therapy in a new era of multiple myeloma management: Trends of engagement and radiologic, biochemical, and cytogenetic correlates of outcomes and response
    Meeting Abstract

    Dreyfuss, A.; Fregonese, B.; Usmani, S. Z.; Mailankody, S.; Imber, B. S.; Yahalom, J.
    Blood (2024)

    Fulltext@MSK | Save